Skip to main content
. 2016 Aug 31;7(40):65418–65428. doi: 10.18632/oncotarget.11739

Figure 3. CHAG inhibits activation of membrane receptors in gastric and hepatic cancer cells.

Figure 3

(A and B) The inhibition of CHAG on phosphorylation/activation of Integrin β1 in AGS cells and HepG2 cells. The cells were serum starved overnight and treated with fibronectin (FN, 1 μg/ml) for 15 min, or with various CHAG solutions (at concentrations of 125, 250, 500, 1000 μg/ml respectively) for 1 h and then with FN (1 μg/ml) for 15 min. (C and D) The inhibition of CHAG on phosphorylation/activation of EGFR in AGS cells and HepG2 cells. The cells were serum starved overnight and treated with EGF (100 ng/ml) for 5 min, or with various CHAG solutions (at concentrations of 125, 250, 500, 1000 μg/ml respectively) for 1 h and then with EGF (100 ng/ml) for 5 min. A–D were representative Western blotting results of three independent experiments. (E and F) were results of densitometry analysis of Western blotting results. (#P < 0.05, compared with control group; *P < 0.05, **P < 0.01, compared with the EGF group).